LOS ANGELES, Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a
leading clinical-stage immuno-oncology imaging company, today
announced the signing of a multi-party collaboration agreement with
AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda
Pharmaceutical Company Limited (Takeda) focused on furthering the
clinical development of ImaginAb's CD8 ImmunoPET technology. Using
its 'Minibody' platform, ImaginAb's technology targets and
visualizes CD8+ T cells to provide highly-specific, quantitative
assessment of the immunological status of each cancer lesion within
a patient, potentially enabling treatment to be tailored quickly
and specifically to the needs of that patient.
Under the terms of the agreement, the collaborators will help
guide a current ImaginAb-sponsored clinical trial that aims to
evaluate the utility and value of CD8 ImmunoPET in immuno-oncology
drug development. In return, the collaborators will gain early
access to clinical and imaging data and collectively contribute to
the post-trial data analysis.
Commenting on the agreement, Ian Wilson, Chief
Executive Officer of ImaginAb, said: "One of our key
objectives is to streamline the clinical development of
next-generation cancer immunotherapies so that ultimately cancer
patients have access to the best possible treatments. We believe
that working with global leaders in immuno-oncology will help us
further develop CD8 ImmunoPET as a pharmacodynamic marker for use
in drug development and, in the future, as a diagnostic and
predictive test for use in hospitals."
Chris Arendt, Head of the
Oncology Drug Discovery Unit at Takeda, said: "We are excited
to participate in this pre-competitive alliance, which brings
together a rich network of expertise and resources to develop and
evaluate an imaging tracer for CD8+ T cells. The ability to track,
both spatially and temporally, immune responses associated with
novel immuno-oncology therapies and relate these to anti-tumor
responses in patients has the potential to deepen our understanding
of the cancer immunity cycle and how it can be leveraged for
curative intent, which is the primary focus of our oncology
research efforts at Takeda."
For further information please contact:
ImaginAb
Ian Wilson
Email: info@imaginab.com
Phone: +1 310 645 1211
Optimum Strategic Communications
Mary Clark, Supriya
Mathur
Email: imaginab@optimumcomms.com
Phone: +44 20 3950 9144
About ImaginAb
ImaginAb, Inc. is an immuno-oncology imaging company focused on
providing actionable insight into patient selection and treatment
progress for cancer immunotherapy, enabling precision medicine.
ImaginAb engineers antibody fragments called minibodies that
maintain the exquisite specificity of full-length antibodies while
remaining biologically inert in the body. Used with widely
available PET scan technology, these novel minibodies illuminate
high-value molecular targets, providing physicians with a
whole-body picture of immune activity. ImaginAb is advancing a
pipeline of minibodies against oncology and immunology targets,
including the CD8 ImmunoPET targeting CD8 T cells. ImaginAb's
products have the potential to improve patient care and lower
healthcare costs. The Company is backed by top tier venture capital
firms and strategic corporate firms, including The Parker Institute
for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad
Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group.
For more information about ImaginAb's pipeline and technology,
visit www.imaginab.com.
About CD8 ImmunoPET
CD8 ImmunoPET minibody [89Zr-Df-IAB22M2C] binds CD8 receptor on
human T cells and is used for non-invasive PET imaging of CD8 T
cells in patients. The Phase 1 dose-escalation study conducted with
cancer patients receiving immunotherapy treatments has demonstrated
safety, established the effective dose and the optimal PET imaging
protocol as well as demonstrated proof of concept for using CD8
ImmunoPET as a clinical tool for the detection and imaging CD8 T
cells in patients. Additional studies including ImaginAb's Phase 2
study and studies sponsored by ImaginAb's corporate partners are
further establishing the repeat dosing and the utility of CD8
ImmunoPET as pharmacodynamic and predictive marker for
immunotherapy.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/imaginab-signs-multi-party-collaboration-agreement-with-three-global-pharmaceutical-companies-to-help-further-develop-companys-cd8-immunopet-technology-300937632.html
SOURCE ImaginAb, Inc.